Activation of the fibrinolytic system in patients with fulminant liver failure

Hepatology

Volumn 18, Issue 6, 1993, Pages 1350-1356

  Pernambuco, J Ricardo B ^a   Langley, Peter G ^a   Hughes, Robin D ^a   Izumi, Satoru ^a   Williams, Roger ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COMPLEMENT COMPONENT C1S INHIBITOR; CREATININE; FIBRIN DERIVATIVE; PARACETAMOL; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG OVERDOSE; FEMALE; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HUMAN; LIVER FAILURE; MALE; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME; SURVIVAL RATE; VIRUS HEPATITIS;

ADOLESCENT; ADULT; AGED; ANTIPLASMIN; ANTITHROMBIN III; COMPLEMENT 1 INACTIVATORS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HUMAN; MALE; MIDDLE AGE; PEPTIDE HYDROLASES; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SUPPORT, NON-U.S. GOV'T;

EID: 0027438332     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.1840180611     Document Type: Article

References (45)

1. Hemostasis in liver disease
2. Coagulation abnormalities in liver disease
3. The blood coagulation cascade
4. PAI‐1 synthesis in the human hepatoma cell line HepG2 is increased by cytokines: evidence that the liver contributes to acute phase behaviour of PAI‐1
5. 2‐antiplasmin inhibitor by established human liver cells lines
6. Synthesis of human plasminogen by the liver
7. Turnover of human extrinsic (tissue‐type) plasminogen activator in rabbits
8. Coagulation abnormalities in acute liver failure: pathogenetic and therapeutic implications
9. Significance of intravascular coagulation and fibrinolysis in acute hepatic failure
10. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage
11. Plasma antithrombin III, alpha 2‐plasmin inhibitor and plasminogen activities in cases of various liver disease
12. Clinical evaluation of tissue plasminogen activator (tPA) levels in patients with liver disease
13. Fibrinogen derivatives and platelet activation products in acute and chronic liver disease
14. The proteinase inhibitor complexes (antithrombin III‐thrombin, alpha 2 antiplasmin‐plasmin and alpha 1 antitrypsin‐elastase) in septicemia, fulminant hepatic failure and cardiac shock: value for diagnosis and therapy control in DIC/F syndrome
15. Coagulation studies as a prognostic index in acute liver failure
16. Intravascular coagulation in acute hepatic necrosis
17. Thrombinantithrombin III complex in fulminant hepatic failure: evidence for disseminated intravascular coagulation and relationship to outcome
18. Intravascular coagulation and the liver
19. Platelet function in chronic liver disease: relationship to disease severity
20. Kinetic and functional studies of platelet, fibrinogen, and plasminogen in patients with hepatic cirrhosis
21. The management of fulminant hepatic failure
22. Leiden fibrinolysis working party: blood collection for assessment of tissue‐type plasminogen activator (t‐PA) and plasminogen activator inhibitor‐1 (PAI‐1)
23. Plasminogen: a brief introduction into its biochemistry and function
24. Progress in fibrinolysis
25. The coagulation‐kinin pathway of human plasma
26. Assay characteristics and fibrin affinity of plasminogen activators of the intrinsic fibrinolytic system
27. The C1 inhibitor deficiency: a review
28. Hepatic clearance of tissue‐plasminogen activator in rats
29. Inhibition of one‐chain and two‐chain forms of human tissue‐type plasminogen activator by the fast‐acting inhibitor of plasminogen activator in vitro and in vivo
30. The effect of fulminant hepatic failure on protein C antigen and activity
31. Induction of endothelial cell synthesis of plasminogen activator inhibitor by t‐PA
32. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2
33. Human HuH‐7 hepatoma cells express urokinase and plasminogen activator inhibitor‐1: identification, characterization and regulation by inflammatory mediators
34. Highly elevated plasma cytokines in fulminant hepatic failure: correlation with multiorgan failure and death [Abstract]
35. Binding uptake and degradation of antithrombin III‐protease complexes by cultured corneal endothelial cells
36. Internalization of antithrombin III by cultured human endothelial cells and its subcellular localization
37. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis
38. Antihaemophilic factor A(F VIII) and serum fibrin‐fibrinogen degradation products in hepatic cirrhosis
39. Tissue plasminogen activator inhibitor in patients with liver cirrhosis
40. Increased levels of fibrinolysis reaction products (D‐dimer) in patients with decompensated alcoholic liver cirrhosis
41. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis
42. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor
43. The extent of diffuse intravascular coagulation and fibrinolysis in patients with liver cirrhosis
44. Fibrinolysis during liver transplantation in humans: role of tissue‐type plasminogen activator
45. Coagulation changes following hepatic revascularisation during liver transplantation